SLU-PP-915: The First Orally-Active Pan-ERR Agonist
The first orally-active pan-ERR agonist — raised exercise capacity in mice even when dosed orally, where its predecessor SLU-PP-332 needed injection.
What is SLU-PP-915?
SLU-PP-915 is a follow-on compound to SLU-PP-332, engineered specifically to retain pan-ERR agonist activity when dosed orally — its predecessor lost effect unless injected. In mice, it increased treadmill exercise capacity in a dose-dependent way, with the effect holding up when given orally, and separately upregulated the same mitochondrial/exercise-response gene program (PGC-1alpha, Ddit4, Pdk4) as SLU-PP-332. Like its predecessor, all supporting data is from mice — no human trial has been published.
Quick facts
- Class
- Orally-active pan-ERR agonist — small molecule, not a peptide
- Solubility
- Oral capsule — no reconstitution required
- Brand Names
- No trademarked brand — sold as a research compound
- Legal Status
- Not FDA-approved for human use — research use only (RUO). No human trials published as of 2026
- Category
- Metabolic / Exercise Mimetic
- Storage
- Room temperature, sealed, away from light and moisture. No refrigeration or reconstitution required.
Dosing at a glance
Doses shown are those reported in published research, not a recommendation.
What the evidence supports
| Claim | Grade | Basis |
|---|---|---|
| Muscle / Exercise Capacity | Dgrade | Billon 2025 (J Pharmacol Exp Ther): dose-dependent exercise-capacity gains in mice, retained when dosed orally — the first orally-active compound in this series. |
| Longevity / Mitochondrial Health | Dgrade | Hampton 2023 (Eur J Med Chem): upregulated PGC-1α and exercise-response genes (Ddit4, Pdk4) in mouse muscle — mechanism-level, animal-only. |
SLU-PP-915 Mechanism of Action
The Same ERR Mechanism, Now Oral
SLU-PP-915 activates the same pan-ERR (estrogen-related receptor) pathway as its predecessor SLU-PP-332, driving the PGC-1α-linked mitochondrial biogenesis and fatty-acid oxidation gene program associated with endurance exercise. Its defining engineering achievement is retaining this activity when dosed orally — SLU-PP-332 required injection to show effects in mice.
Exercise Capacity, Not Just Metabolic Markers
SLU-PP-915's headline mouse result is functional, not just biochemical: increased treadmill exercise capacity, in a dose-dependent way, that held up when the compound was given orally — a more direct performance readout than the fat-mass/gene-expression endpoints emphasized in SLU-PP-332's data.
SLU-PP-915 Dosage and Protocols
Research Protocol Range
Research-vendor products are commonly dosed at 10-25mg orally once daily. Since no human trial exists, this range reflects informal research-community convention extrapolated from mouse dosing, not validated human guidance.
SLU-PP-915 Side Effects and Safety
No Human Safety Data
Because no human trial has been published, there is no characterized human side-effect profile for SLU-PP-915. Active malignancy is treated as a precautionary contraindication given the broad nuclear-receptor mechanism affecting cellular metabolism genome-wide.
SLU-PP-915 Research Evidence
First Oral Compound in This Class to Work
Billon et al. (2025, J Pharmacol Exp Ther) reported dose-dependent exercise-capacity gains in mice that were retained when the compound was dosed orally (adjusted for exposure) — the first orally active compound in the SLU-PP series to show this. An earlier 2023 discovery paper (Xu et al., Eur J Med Chem) found a single injected dose raised exercise-response genes, and a 6-day course enhanced endurance.
Regulatory and Legal Status
SLU-PP-915 is not FDA-approved and has never been studied in humans as of 2026 — like its predecessor, every claim rests on mouse data. It is sold exclusively as a research-grade compound (RUO). Researchers and users should verify the legal status of SLU-PP-915 in their jurisdiction prior to purchase or use.
SLU-PP-915 Stacking and Combinations
An Oral Alternative to SLU-PP-332
SLU-PP-915 is generally used as an oral alternative to injectable SLU-PP-332 rather than combined with it — both target the same ERR pathway, so stacking them wouldn't add a distinct mechanism.
SLU-PP-915 Pharmacokinetics
First Orally Bioavailable Compound in Its Class
No formal human pharmacokinetic study exists, but SLU-PP-915's defining property — relative to SLU-PP-332 — is retaining meaningful exposure and effect when dosed orally in mice, the property its structural optimization specifically targeted.
Contraindications
- pregnancy
- active malignancy
Trials and reviews
- Billon oral ERR agonistJ Pharmacol Exp Ther2025
Dose-dependent exercise-capacity gains in mice, retained orally
- Hampton discovery (compound 10s)Eur J Med Chem2023
Raised exercise-response genes after a single dose; 6-day course enhanced endurance
Frequently asked questions
What is a typical SLU-PP-915 dose?
Published research protocols report 10–25 mg, 1x daily. This is the range described in the literature, not a recommendation.
What is the half-life of SLU-PP-915?
Not established in humans.
Is SLU-PP-915 backed by strong evidence?
SLU-PP-915 carries a REGEN research grade of D. REGEN Research Tier D — mouse data only, no published human trials as of 2026.
How is SLU-PP-915 administered?
Routes reported in the literature: oral.
Who should avoid SLU-PP-915?
Contraindications noted in the literature include pregnancy, active malignancy.
References
- SLU-PP-915 orally-active ERR agonist exercise study · Billon C, et al. · 2025